Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Progressive diaphyseal dysplasia is characterized clinically by crippling leg pain, fatigue, headache, poor appetite, muscle weakness, and waddling gait. Twelve affected patients, aged 2 years 4 months to 40 years, were treated with intermittent courses of low doses of prednisone given in a single dose on alternate mornings for periods ranging from 6 months to 10 years. The average initial dose of prednisone was 0.6 mg/kg/d, and average maintenance dose was 0.3 mg/kg/d. Relief of all crippling symptoms was achieved in all patients. No untoward serious side effects have been observed, and the growth of children was not slowed. However, corticosteroid therapy should be restricted to patients suffering from crippling pain. The mechanism through which steroids act remains undefined.
 ...
PMID:Progressive diaphyseal dysplasia: evaluation of corticosteroid therapy. 396 34

A new "normophasic" oral contraceptive, Fisioquens (7 tablets of .05 mg ethinylestradiol, and 15 tablets with .05 mg ethinylestradiol and 1 mg lynestrenol) was taken by 120 fertile women for an average of 9.24 cycles, maximum of 12 cycles, and a total of 1108 cycles. There were no pregnancies, no drug related drop outs, good menstrual control and very few side effects. Latent period before withdrawal bleeding was 2-3 days in 89.9% of cycles. Bleeding lasted 4.5 days in 72% of cycles, occurred every 28 days in 88%, was usually the same in amount, sometimes increased. There was breakthrough bleeding in .38% of cycles, spotting in 2%, and amenorrhea in only 2 cycles. Side effects included nausea (worsened in 3.3%, improved in 5%); headache (worsened in 9.1%, improved in 10.8%); breast pain (worsened in 7.5%, improved in 17.5%); leg pain (worsened in 8.3%, improved in 7.5%); leucorrhea (worsened in 1.6%, improved in 30.8%); psychological status (worsened in 2.4%, improved in 7.5%). Whether the patients had previously been taking other pills was not stated. The author concluded that this formulation was efficacious and acceptable because it resembles a sequential, but gives longer protection of progestagen.
 ...
PMID:[Clinical study of a new, normophasic type oral contraceptive]. 477 56

147 Mexican women, of low socioeconomic level, who had aborted spontaneously and desired pregnancy, were subjected to trial of placebo oral contraceptive. In 424 months there were 72 pregnancies, a Pearl index of 203.8 pregnancies per 100 couple-years. Menstrual cycles lasted 21-24 days in 30 women (9.8%), 25-35 days in 235 (76.8%), and 36-59 days in 38 (12.4%). 18 cycles (5.8%) were marked by intermenstrual bleeding. Incidence of 31 side effects is listed. Most common were: decreased libido 125 months (29.5%), headache 66 (15.6%), lower abdominal pain and bloating 58 (13.7%), dizziness 47 (11.1%). Common complaints were nervousness, increased libido, dysmenorrhea, nausea, epigastric pain, leg pain, leukorrhea, somnolence. Oral contraceptive-like side effects reported in fewer than 1% of months included acne, mastalgia, increased appetite, weight gain, painful varicose veins. Nausea (here 4.2% of months) was the only side effect with markedly different incidence from other studies with active oral contraceptives.
 ...
PMID:Incidence of side effects with contraceptive placebo. 535 96

In a comparative randomized double-blind study, 73 patients underwent myelography using iopamidol (36 patients) or metrizamide (37 patients) as contrast medium. The overall diagnostic adequacy of iopamidol myelography was found to be comparable to that of metrizamide myelography. The incidence of examinations graded as superior (64%) or adequate (36%) with iopamidol was equivalent to that with metrizamide (57% superior, 43% adequate). Adverse reactions after iopamidol myelography were fewer, less severe, and generally of shorter duration than those associated with metrizamide. In the iopamidol group, adverse reactions occurred in nine (25%) patients, all of whom experienced mild or moderate headache, one with nausea, vomiting, and fatigue. In the metrizamide group, adverse reactions occurred in 17 (46%) patients, all of whom experienced mild or moderate headache, six with nausea and vomiting and four with back and leg pain. Of nine individuals who underwent myelography using 300 mg 1/ml metrizamide injected via lateral C1-C2 puncture, three experienced a toxic encephalopathy with confusion, dysphasia, headache, nausea, and vomiting, and a fourth individual suffered severe nausea, vomiting, fever, and irregular pulse. Encephalopathy was not observed in any of the 11 patients in whom myelography was performed via lateral C1-C2 puncture with a similar concentration of iopamidol. No seizures were encountered, and no clinically significant changes in laboratory studies were observed with either contrast medium.
 ...
PMID:Iopamidol and metrizamide for myelography: prospective double-blind clinical trial. 638 81

A randomized double-blind study was conducted to compare the radiographic quality and adverse reactions in myelography of the two nonionic water-soluble contrast media, iopamidol and metrizamide. A total of 46 myelograms were obtained, 28 with iopamidol and 18 with metrizamide. Untoward reactions consisted of nausea, headaches, back and leg pain, neuropsychiatric findings, and urinary retention. Iopamidol caused no reactions in 20 of the 28 cases, while metrizamide caused no reactions in only three of 18 cases. Film quality evaluation showed 22 of the 28 studies with iopamidol were judged excellent, whereas only 11 of the 18 metrizamide studies were judged excellent. The results of this study suggest that iopamidol produces better quality studies with fewer and milder adverse reactions than metrizamide.
 ...
PMID:Comparison of radiographic quality and adverse reactions in myelography with iopamidol and metrizamide. 641 Jul 30

The results of the initial North American trial of the nonionic, water-soluble contrast medium iopamidol for lumbosacral myelography are reported. The iopamidol was easily visualized by fluoroscopy during introduction, and the radiographic quality of all 12 conventional myelographic examinations was excellent. The diagnoses were herniated nucleus pulposus (seven), traumatic dislocation (one), metastasis (one), and normal (three). One patient had a repeat myelogram with a different hydrosoluble contrast medium 2 months after his iopamidol examination and surgery and showed no radiographic evidence of arachnoiditis. The adverse reactions were all mild and transient: headache (four cases), nausea (two), and leg pain (one). There were no diaphoresis, fever, seizures, hallucinations, agitation, or vital sign changes. Electrocardiography, hematology, and blood chemistries were all normal. In two patients, electroencephalogram changes, three to four bursts of diffuse intermittent rhythmic delta activity with no spiking, were present at 6 hr with return to normal at 24 hr.
 ...
PMID:Clinical trial of iopamidol for lumbosacral myelography. 680 Feb 40

A patient with disabling postural tachycardia without postural hypotension had symptoms that included palpitations, weakness, abdominal and leg pain, light-headedness, headache and diaphoresis that occurred only in the upright position. She was shown to have an enhanced sympathetic neural response to standing (exaggerated plasma nor epinephrine response), and her cardiovascular responsiveness to released catecholamines was clearly intact. However, she was unable to maintain normal sodium balance and had a measurably reduced plasma volume while consuming normal amounts (120 mmol daily) of dietary sodium. Sodium loading (240 mmol ingested daily plus administration of fluorohydrocortisone, 0.1 mg daily) largely corrected the hemodynamic abnormalities, prevented postural symptoms and caused the compensatory sympathetic response to revert to normal.
 ...
PMID:Postural tachycardia syndrome. Reversal of sympathetic hyperresponsiveness and clinical improvement during sodium loading. 708 Dec 80

Perimenstrual symptoms are among the most common disorders of women. Seven perimenstrual symptoms were related to working conditions among 539 hospital workers in a retrospective cohort questionnaire study, as part of a larger examination of health problems and working conditions of Quebec hospital workers. Only 8% of women had experienced no symptoms of discomfort associated with their last menstrual period. Lower abdominal pain, the most common symptom (58% prevalence), was associated with lifting weights (usually patients) in a logistic regression adjusted for parity and contraceptive use. Back pain, leg pain, swelling, and headache were associated with indicators of time pressure and fast work speed. Back pain during menstruation was experienced by 44% of workers. Studies of the prevalence and etiology of back pain, a common occupational health problem among hospital workers, may be confused if perimenstrual back pain is not taken into account. Similar reservations hold for the results on other perimenstrual symptoms that are also likely to occur outside the perimenstrual period, such as leg pain, irritability, and headache.
 ...
PMID:Perimenstrual symptoms and working conditions among hospital workers in Quebec. 779 22

The effect of alpha 1-adrenoceptor blockade (doxazosin, 4 mg daily) on maximal VO2 and physical endurance capacity in 16 mildly hypertensive, athletic men was investigated in a randomized, placebo-controlled, double-blind, two-period of 4 weeks, cross-over study. The maximal workload obtained during graded bicycle ergometer exercise and the corresponding maximal VO2 were reduced by 16 +/- 3 W (mean +/- SE), (P = .00003) and 3 +/- 1 mL/(kg.min) (P = .0004), respectively, on doxazosin compared with placebo. The running time on a 5000 m track increased by 43 +/- 12 sec on doxazosin (P = .04). Heart rate was unchanged during the running session. Systolic blood pressure was reduced by 9 +/- 4.1 mm Hg (P = .04) immediately after finishing 5000 m. Six subjects reported side effects from doxazosin (headache, fatigue, and leg pain). Thus, antihypertensive treatment with alpha 1-selective adrenoceptor blockade moderately, but significantly, reduces maximal O2 consumption and high intensity physical endurance capacity in mildly hypertensive athletic men. Significantly reduced systolic blood pressure and unchanged heart rate immediately after running, combined with unchanged heart rate during the race may, however, suggest a safer exercise performance.
 ...
PMID:Effect of alpha 1-adrenoceptor blockade on maximal VO2 and endurance capacity in well-trained athletic hypertensive men. 794 61

Out-patient lumbar myelography was carried out on 74 consecutive patients, and adverse reactions were registered by the patients themselves. Twenty-four percent experienced moderate or severe headache; 62% experienced increasing back pain of a moderate or severe degree; 40% experienced increasing leg pain of a moderate or severe degree; 15% experienced nausea/general symptoms to a moderate or severe degree. Twenty-nine percent experienced the myelography as unpleasant in a moderate or severe degree. Fourty-seven percent had some kind of adverse reaction for > or = four days. Eleven patients (16%) were admitted to hospital because of severe adverse reactions, mostly headache, and nine of them were treated with a blood patch. Twenty-five percent were referred for operation for their back disease. Generally, out-patient lumbar myelography is well tolerated, but a large proportion of the patients experience temporary adverse reactions to a moderate or severe degree, perhaps in part because of immobilisation in connection with photographing procedures.
 ...
PMID:[Ambulatory lumbar myelography]. 798 64


<< Previous 1 2 3 4 5 6 7 Next >>